In most bacteria, the essential targets of β-lactam antibiotics are the D,D-transpeptidases 16 that catalyze the last step of peptidoglycan polymerization by forming 4→3 cross-links. 17 The peptidoglycan of Clostridium difficile is unusual since it mainly contains 3→3 cross-18 links generated by L,D-transpeptidases. To gain insight into the characteristics of C. 19 difficile peptidoglycan cross-linking enzymes, we have purified the three putative C. 20 difficile L,D-transpeptidases paralogues, Ldt Cd1 , Ldt Cd2 , and Ldt Cd3 , which have been 21 previously identified by sequence analysis. The catalytic activity of the three proteins 22 was assayed with a disaccharide-tetrapeptide purified form the C. difficile cell wall. 23 Ldt Cd2 and Ldt Cd3 catalyzed the formation of 3→3 cross-links (L,D-transpeptidase 24 activity), the hydrolysis of the C-terminal D-Ala residue of the disaccharide-tetrapeptide 25 substrate (L,D-carboxypeptidase activity), and the exchange of the C-terminal D-Ala by 26 D-Met. Ldt Cd1 only displayed L,D-carboxypeptidase activity. Mass spectrometry analyses 27 indicated that Ldt Cd1 and Ldt Cd2 were acylated by β-lactams belonging to the 28 carbapenem (imipenem, meropenem, and ertapenem), cephalosporin (ceftriaxone), and 29 penicillin (ampicillin) classes. Acylation of Ldt Cd3 by these β-lactams was not detected.
the disaccharide-tetrapeptide were incubated for 3 h and formation of the products was 91 assayed by mass spectrometry. Incubation of Ldt Cd2 and Ldt Cd3 with the disaccharide-92 tetrapeptide substrate resulted in the formation of a dimer and a disaccharide-tripeptide 93 indicating that these enzymes display both L,D-transpeptidase (LDT) and L,D-94 carboxypeptidase (LD-CPase) activities ( Fig. 1A and Table 1 ). The dimer contained a 3→3 95 cross-link connecting two disaccharide-tripeptides (Table 1) . This may imply two mutually 96 non-exclusive reaction schemes involving both the LDT and LD-CPase activities of Ldt Cd2 97 and Ldt Cd3 . For the first reaction scheme, the disaccharide-tripeptide generated by the CPase activity is used as the acyl-acceptor substrate to generate the dimer (as depicted in Fig.   99 1A). For the second reaction scheme, the cross-linking reaction involves an acyl acceptor 100 containing a tetrapeptide stem and D-Ala 4 is cleaved off from the dimer by the LD-CPase 101 activity.
102
Formation of an acyl-enzyme is a common intermediary for the LDT and LD-CPase 103 activities ( Fig. 1A) . Prior analyses of the LDT from E. faecium (Ldt fm ) have shown that the Table 1 ). In M. tuberculosis, one of the five L,D-transpeptidase paralogues (Ldt Mt5 ) similarly 116 catalyzes formation of peptidoglycan dimers in vitro in the absence of detectable acylation by 117 β-lactams (18).
118
For Ldt Cd1 and Ldt Cd2 , mass spectrometry analysis revealed the formation of acyl-119 enzymes for representatives of three classes of β-lactams (Table 2) . For carbapenems, the 120 mass of the acyl-enzymes (EI*) corresponded to the mass of the proteins plus the mass of the 121 β-lactam indicating the presence of the entire drugs in the covalent adducts ( Fig. 2) . Acylation 122 of the L,D-transpeptidases by the cephalosporin ceftriaxone led to the loss of the R 2 side-chain 123 (acyl-enzyme EI**). The acyl-enzyme containing the complete drug (EI*) was not detected 124 suggesting a concerted mechanism involving simultaneous acylation and loss of the R 2 side-125 chain, as previously described (17, 19) . Incubation of LDTs with ampicillin led to the 126 formation of two acyl-enzymes containing the complete drug (EI*) or a drug fragment was tentatively identified as CD3007 but attempts for its inactivation were unsuccessful (9).
191
In the current study, purification of the product of CD3007 showed that this enzyme is indeed Supplementary Table 1 . 206 Each ldt Cd gene was independently amplified with two sets of primers (A1 plus A2 and B1 207 plus B2). The amplicons A1-A2 and B1-B2 were purified by agarose gel electrophoresis, 208 mixed, denatured, and annealed. Since the extremity of the amplicons A1-A2 and B1-B2 Transparency declaration 269 We have no competing interests to declare. 
